Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats

Nur Ozten, Katherine Vega, Joachim Liehr, Xi Huang, Lori Horton, Ercole Cavalieri, Eleanor G Rogan, Maarten C. Bosland

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16–75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37% of rats. 5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%). Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%), unlike adding estradiol to testosterone treatment which induced a 100% tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by 32 P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21%). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled. These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.

Original languageEnglish (US)
JournalHormones and Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Androgens
Testosterone
Prostate
Prostatic Neoplasms
Estrogens
Carcinogenesis
Estradiol
Dihydrotestosterone
Incidence
Neoplasms
DNA Adducts
Androgen Receptors
Estrogen Receptors
Lipid Peroxidation
DNA Damage

Keywords

  • Androgen
  • Estrogen
  • Hormonal carcinogenesis
  • Prostate cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cancer Research

Cite this

Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats. / Ozten, Nur; Vega, Katherine; Liehr, Joachim; Huang, Xi; Horton, Lori; Cavalieri, Ercole; Rogan, Eleanor G; Bosland, Maarten C.

In: Hormones and Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Ozten, Nur ; Vega, Katherine ; Liehr, Joachim ; Huang, Xi ; Horton, Lori ; Cavalieri, Ercole ; Rogan, Eleanor G ; Bosland, Maarten C. / Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats. In: Hormones and Cancer. 2019.
@article{5e3d4c2f89424505b1cc214bfcb98458,
title = "Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats",
abstract = "Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16–75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37{\%} of rats. 5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4{\%}). Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14{\%}), unlike adding estradiol to testosterone treatment which induced a 100{\%} tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by 32 P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21{\%}). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled. These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.",
keywords = "Androgen, Estrogen, Hormonal carcinogenesis, Prostate cancer",
author = "Nur Ozten and Katherine Vega and Joachim Liehr and Xi Huang and Lori Horton and Ercole Cavalieri and Rogan, {Eleanor G} and Bosland, {Maarten C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12672-019-00360-7",
language = "English (US)",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",

}

TY - JOUR

T1 - Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats

AU - Ozten, Nur

AU - Vega, Katherine

AU - Liehr, Joachim

AU - Huang, Xi

AU - Horton, Lori

AU - Cavalieri, Ercole

AU - Rogan, Eleanor G

AU - Bosland, Maarten C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16–75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37% of rats. 5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%). Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%), unlike adding estradiol to testosterone treatment which induced a 100% tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by 32 P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21%). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled. These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.

AB - Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites. We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16–75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37% of rats. 5α-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%). Addition of estradiol to 5α-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%), unlike adding estradiol to testosterone treatment which induced a 100% tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by 32 P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21%). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled. These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.

KW - Androgen

KW - Estrogen

KW - Hormonal carcinogenesis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85062990795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062990795&partnerID=8YFLogxK

U2 - 10.1007/s12672-019-00360-7

DO - 10.1007/s12672-019-00360-7

M3 - Article

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

ER -